XFOR
X4 Pharmaceuticals Inc
NASDAQ · Biotechnology
$3.56
-0.10 (-2.73%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 56.15M | 57.05M | 55.03M |
| Net Income | 11.50M | 9.29M | 9.37M |
| EPS | — | — | — |
| Profit Margin | 20.5% | 16.3% | 17.0% |
| Rev Growth | +18.4% | +3.4% | -0.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 127.21M | 127.66M | 98.88M |
| Total Equity | 122.94M | 135.98M | 129.32M |
| D/E Ratio | 1.03 | 0.94 | 0.76 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 17.32M | 17.50M | 15.80M |
| Free Cash Flow | 7.07M | 7.43M | 8.43M |